Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
Why BioNTech Stock Climbed Today
06:53pm, Monday, 09'th May 2022 The Motley Fool
Global demand for the vaccine maker's COVID-19 drug remains strong.
J&J (JNJ) Updates COVID Jab Label to Include Blood Clot Risk
03:09pm, Monday, 09'th May 2022 Zacks Investment Research
J&J's (JNJ) decision to update the label of its COVID-19 vaccine came on the heels of the FDA's decision to limit the authorized use of its vaccine due to the risk of TTS.
New study finds omicron no less severe than earlier variants, and not just more transmissible
12:16pm, Monday, 09'th May 2022 MarketWatch
A new study conducted by researchers at Harvard Medical School among others has found that the omicron variant of the coronavirus that causes COVID-19 is just as severe as earlier variants, and not mo
Jim Cramer Shares His Thoughts On Chubb, Novavax And More
12:13pm, Monday, 09'th May 2022 Benzinga
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes the long-term prospects of Plug Power Inc (NASDAQ: PLUG). "Right now, this is a very tough day for a stock like Plug Power," he added
Could Novavax Stock Help You Retire a Millionaire?
11:05am, Monday, 09'th May 2022 The Motley Fool
This biotech company isn't just a COVID-19 play.
2 Healthcare Stocks That Could Make You Richer
12:07pm, Saturday, 07'th May 2022 The Motley Fool
The long-term outlook seems great for both of these companies.
Why GSK May Have Bet Too Big on a Pandemic Pipeline
11:57am, Saturday, 07'th May 2022 The Motley Fool
Its late-stage pipeline is heavily weighted toward pandemic treatments.
3 Unstoppable Stocks to Buy in May
11:03am, Saturday, 07'th May 2022 The Motley Fool
These big drugmakers should be long-term winners.
Novavax: Don't Catch The Falling Knives
05:52am, Saturday, 07'th May 2022 Seeking Alpha
Novavax is scheduled to report its Q1 earnings on May 9. Read more to see why we think investors should avoid catching this falling knife.
Theravance's (TBPH) Q1 Earnings and Sales Miss Estimates
08:15pm, Friday, 06'th May 2022 Zacks Investment Research
Theravance (TBPH) reports wider-than-expected loss for the first quarter of 2022. Revenues decline year over year.
Drug companies are making an accounting change after the SEC cracked down on Biogen
05:07pm, Friday, 06'th May 2022 MarketWatch
Reporters and analysts covering first-quarter earnings from drug companies may have noticed a change in how they account for upfront payments made to finance research and development at companies in w
Fundamentals Of U.S. Stocks Dominating Major Indices Are More Important Than Ever
04:14pm, Friday, 06'th May 2022 Investing.com
Is Pfizer Too Dependent on COVID-19 Revenue?
03:30pm, Friday, 06'th May 2022 The Motley Fool
How strong is the rest of the company's portfolio?
3 Top Biotech Stocks to Buy Right Now
02:45pm, Friday, 06'th May 2022 The Motley Fool
These three pharma stocks each pay market-beating dividends to shareholders.
Nektar's (NKTR) Q1 Earnings Top, Workforce Reduction on Track
02:07pm, Friday, 06'th May 2022 Zacks Investment Research
Nektar (NKTR) reports encouraging first-quarter 2022 results. The company remains on track with its restructuring plans following the discontinuation of bempeg development.
